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Abstract 
Background: Results of longitudinal researches regarding the temporal relationship between dyslipidemia and insu-
lin resistance (IR) are inconsistent. This study assessed temporal relationships of blood lipids with IR and determined 
whether there are any mediating effects existed in these temporal relationships.
Methods: This study examined a longitudinal cohort of 3325 subjects aged 20–74 years from China with an average 
of 4.2 years follow-up. Measurements of fasting blood lipids, as well as fasting and 2-h serum glucose and insulin, were 
obtained at two time points. The Gutt index and HOMA-IR were calculated as indicators of peripheral IR and hepatic 
IR. A cross-lagged path analysis was performed to examine the temporal relationships between blood lipids and IR. A 
mediation analysis was used to examine mediating effect.
Results: After adjusting for covariates, the cross-lagged path coefficients from baseline TG and HDL-C to follow-up 
Gutt index were significantly greater than those from baseline Gutt index to follow-up TG and HDL-C (β1 = −0.131 
vs β2 = −0.047, P < 0.001 for TG; β1 = 0.134 vs β2 = 0.023, P < 0.001 for HDL-C). The path coefficients from baseline 
TG and HDL-C to follow-up 2-h insulin were significantly greater than those from baseline 2-h insulin to follow-up TG 
and HDL-C (β1 = 0.125 vs β2 = 0.040, P < 0.001 for TG; β1 = −0.112 vs β2 = −0.026, P < 0.001 for HDL-C). 2-h insulin 
partially mediated the effect of TG/HDL-C on Gutt index with a 59.3% mediating effect for TG and 61.0% for HDL-C.
Conclusions: These findings provide strong evidence that dyslipidemia probably precede peripheral IR and that 2-h 
insulin partially mediates this unidirectional temporal relationship.
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Background
Both dyslipidemia and insulin resistance (IR) are patho-
genetic factors that are fundamental contributors to the 
development of type 2 diabetes and cardiovascular dis-
ease. Although the strong association between these 
pathogenetic factors has long been recognized [1–3], 
it is largely unknown which factor is the precursor, or 
whether the temporal relationship between them is bidi-
rectional [4, 5]. Therefore, it is necessary to clarify the 
temporal relationship between these factors in order to 
provide an early and effective target for preventing type 2 
diabetes (T2D) and cardiovascular disease (CVD).
The temporal relationship between dyslipidemia and 
IR is a “chicken-and-egg” question in basic research. 
Through multiple mechanisms, the metabolites of tri-
glycerides (TG) can interfere with insulin-signaling path-
ways, while high-density lipoprotein cholesterol (HDL-C) 
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can improve IR in target tissues [6, 7]. On the other hand, 
IR stimulates lipogenesis and cholesterol synthesis, which 
results in the overproduction of hepatic very low density 
Lipoprotein (VLDL), inducing dyslipidemia [8]. Results 
of longitudinal researches regarding on this issue have 
also been inconsistent. Some investigators demonstrated 
that baseline IR was associated with the incidence of 
dyslipidemia [9, 10]. Alternatively, others demonstrated 
that blood lipids were a long-term predictor of IR [11]. 
Notably, in these longitudinal studies, the exclusion of 
subjects with dyslipidemia or IR traits at baseline based 
on their study hypothesis favored a one directional result 
and limited the other directional result (i.e., the exclusion 
of subjects with dyslipidemia at baseline favors the result 
that IR precedes dyslipidemia and limits the other result 
that dyslipidemia precedes IR). This type of study design 
and statistical analysis are likely the main reasons why 
the results from these longitudinal studies are inconsist-
ent thus far.
In this study, we adopted a cross-lagged path analysis 
to explicitly assess the temporal relationship between 
dyslipidemia and IR using a longitudinal data of China. 
The cross-lagged path analysis is a model to assess causal 
associations in data derived from non-experimental, lon-
gitudinal research design [12]. This theoretical model has 
been successfully used to analysis the temporal relation-
ship between inter-related variables in previous studies 
[13, 14]. According to this theoretical model, if the rela-
tionship between dyslipidemia and IR was bidirectional, 
they would predict each other, and their cross-lagged 
path coefficients would not be significantly different. 
However, if IR and dyslipidemia have an underlying 
causal relationship, the causal variable should predict the 
consequent variable, and the cross-lagged path coeffi-
cient of the causal variable should be significantly greater 
than that of the consequent variable. We also analyzed 
whether there were any mediating effects existed in 




The participants were from the Harbin People’s 
Health Study (HPHS). The HPHS was launched by 
the Centers for Disease Control and Prevention and 
the Public Health School in Harbin in 2008 [15]. It 
covered five urban administrate regions of Harbin. 
Each region were divided into three strata based on 
their financial situation and one or two neighbor-
hood committees were chosen from 15 communities 
that were randomly selected from each stratum in 
each administrate region by performing a stratified 
multistage random cluster sampling design. A total of 
8940 subjects, aged 20–74  years, were recruited for 
the study. Subjects were eligible to participate in the 
study if they had no history of postmenopausal hor-
mone therapy, malignancy, thyroid dysfunction, renal 
calculi, or corticosteroid or calcitriol use. A total of 
4515 subjects (approximately 50.5% of the total sub-
jects) were selected by completely randomized sam-
pling method to participate in a follow-up survey due 
to the financial limitations of this study. In 2012, 4158 
subjects completed the first in-person follow-up sur-
vey, for a response rate of 92.1%. The basic informa-
tion did not differ significantly between the original 
cohort and the selected cohort. After the exclusion of 
398 subjects who were taking hypoglycemic drugs or 
insulin injections, and 435 subjects who were receiv-
ing dyslipidemia treatment at either the baseline or the 
follow-up survey, 3325 subjects were included in this 
analysis, with an average follow-up period of 4.2 years. 
These 3325 subjects included 633 subjects with type 
2 diabetes who were not receiving any treatment and 
1887 subjects with dyslipidemia who were not receiv-
ing dyslipidemia medication at either baseline or the 
follow-up survey. The study protocols were approved 
by the Ethics Committee of Harbin Medical University, 
and written informed consent was provided by all sub-
jects. The methods in this study were in accordance 
with the approved guidelines.
Questionnaire survey
Detailed in-person interviews were administered by 
trained personnel using a structured questionnaire to 
collect information on demographic characteristics, die-
tary habits, lifestyles, physical condition and anthropo-
metric characteristics. Current smokers were defined as 
those who smoked at least 100 cigarettes in a lifetime or 
smoked every day or currently smoked some days. Cur-
rent drinkers were defined as those who consumed ≥1 
alcoholic drink each month in the 12 months prior to the 
survey. Regular exercise was defined as any kind of rec-
reational or sport physical activity other than walking for 
work or life performed at least 30 min for 3 or more days 
per week.
Anthropometric measurements
Anthropometric measurements, including height, weight, 
and waist circumference, were obtained by well-trained 
examiners, with the participants wearing light, thin cloth-
ing and no shoes. Body weight and height were measured 
to the nearest 0.1 kg and 0.1 cm, respectively. Body mass 
index (BMI) was calculated as weight (kg) divided by the 
square of the height in meters (m2). An oral glucose toler-
ance test was performed, according to the World Health 
Organization guidelines, for each subject.
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Biochemical analyses
Fasting serum lipids, including total cholesterol (TCHO), 
TG, low-density lipoprotein cholesterol (LDL-C), HDL-
C, and fasting and 2-h serum glucose were measured 
using an automatic biochemistry analyzer (Hitachi 
7100, Tokyo, Japan). Fasting and 2-h serum insulin was 
measured by immunofluorescence method (TOSOH 
automated enzyme immunoassay (EIA) analyzer AIA-
2000ST). Gutt index was calculated as an indicator of 
peripheral IR, which is based on glucose uptake rates, 
metabolic clearance rates and mean serum insulin by 
the following equation: [75,000 + (fasting glucose − 2-h 
glucose)  ×  0.19  ×  body weight]/(120  ×  log [(fasting 
insulin +  2-h insulin)/2] ×  [(fasting glucose +  2-h glu-
cose)/2]) [16]. HOMA models were used to estimate 
hepatic insulin resistance (HOMA-IR) and beta cell func-
tion (HOMA-%β) with HOMA2 calculator updated by 
the University of Oxford in 2004 [17].
Outcome measures
Diabetes was identified by self-reports of a history of dia-
betes diagnosis, fasting blood glucose ≥7.0 mmol/L, and/
or 2-h glucose ≥11.1 mmol/L, and/or receiving treatment 
for diabetes. Dyslipidemia was identified by self-reports 
of a dyslipidemia diagnosis history, and/or hypercholes-
terolemia (fasting TCHO ≥6.22  mmol/L, and/or fast-
ing LDL-C ≥4.14 mmol/L), and/or hypertriglyceridemia 
(fasting serum TG ≥2.26  mmol/L), and/or low HDL-C 
[fasting serum HDL-C <1.04  mmol/L (male), fasting 
serum HDL-C <1.29 mmol/L (female)], and/or receiving 
treatment for dyslipidemia.
Statistical analysis
All statistical analyses were performed using R 2.15.3 
(http://www.r-project.org/) and LISREL 8.52. A two-
sided P  <  0.05 was considered statistically significant. 
Blood lipids, HOMA-IR, HOMA-%β, Gutt index and 
insulin were log-transformed to improve the normality of 
the distribution.
Generalized linear models were performed to test dif-
ferences in continuous variables between gender and 
menopause status and calculate covariate-adjusted 
mean yearly rates of change in Blood lipids, HOMA-IR, 
HOMA-%β, Gutt index and insulin during the follow-
up period. Univariate and multivariate linear regression 
models were used to determine which type of baseline 
blood lipids independently predicted future HOMA-IR, 
HOMA-%β, Gutt index and insulin.
Longitudinal changes in blood lipids, HOMA-IR, 
HOMA-%β, Gutt index and insulin measured at two time 
points can be modeled using a cross-lagged panel design. 
In this modeling approach, each variable in the model is 
regressed on all of the variables that precede it in time. A 
simplified, conceptual version of the model used in this 
analysis is presented in Fig.  1. The path coefficient with 
β1 describes the effect of baseline TG or HDL-C on the 
subsequent Gutt index, and the path coefficient with β2 
describes the effect of the baseline Gutt index on the sub-
sequent TG or HDL-C. Prior to the cross-lagged path 
analysis, the baseline and follow-up biochemical indi-
ces were adjusted for age, gender, alcohol consumption, 
smoking, regular exercise, BMI, and caloric intake using 
a regression residual analysis and then were standard-
ized by Z-transformation (mean = 0, standard deviation, 
1). Pearson correlation coefficients of the Z-transformed 
quantitative variables of biochemical indices at baseline 
and follow-up were calculated. The cross-lagged path 
coefficients (β1 and β2) were estimated simultaneously 
based on the correlation matrix using the maximum like-
lihood method in LISREL version 8.52. The percentile 
confidence interval of cross-lagged path coefficient was 
estimated using bootstrap simulation for the cross-lagged 
model. The validity of model fitting was indicated by the 
root mean square residual (RMR) and comparative fit-
ness index (CFI) [18, 19]. RMR < 0.05 and CFI > 90 indi-
cate relatively good fit to the observed data. The temporal 
relationships of blood lipids with Gutt index, HOMA-
models and 2-h insulin were examined in separate mod-
els. The difference between β1 and β2 derived from the 
standardized variables was tested using Fisher’s Z-test 
[14]. Although the significance of individual β1 or β2 sug-
gests a directional relationship, a significant difference 
between β1 and β2 provides stronger evidence for a tem-
poral relationship in the model.
Once the temporal relationships of these biochemical 
indices had been established, a causal mediation model 
was constructed to examine whether there are any medi-
ating effects existing in these temporal relationships 
using R package mediation.
Results
The characteristics regarding the study variables
Additional file 1: Table S1 summarizes the mean levels of 
the study variables at baseline and follow-up by gender 
and menopausal status. The mean levels of continuous 
variables with adjustment for age (except age itself ) and 
dichotomous variables were compared between genders 
and pre- and post-menopausal females.
The association of baseline blood lipids profile 
with follow‑up IR‑related indices by linear regression 
analysis
Results of univariate and multivariate linear regression 
models are presented in Table 1. Baseline TG and HDL-C 
independently predicted the follow-up Gutt index, 
HOMA-IR, HOMA-%β and 2-h insulin (P  <  0.05) after 
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adjusting for age, gender, smoking, alcohol consumption, 
regular exercise, BMI, caloric intake and the baseline 
dependent variables, whereas TCHO and LDL-C did not. 
Therefore, based on the result of the linear regression 
model, we further analyzed the temporal relationships 
of TG and HDL-C with these indices in the cross-lagged 
path analysis.
The cross‑lagged path analysis of TG and HDL‑C 
with IR‑related indices
The cross-lagged path coefficients with adjustment for 
age, gender, smoking, alcohol consumption, regular 
exercise, BMI and caloric intake are presented in Table 2 
and Fig.  1. The path coefficients (β1) from the baseline 
TG to the follow-up Gutt index and 2-h insulin were sig-
nificantly greater than the path coefficients (β2) from the 
baseline Gutt index and 2-h insulin to the follow-up TG 
(both P < 0.001 for the difference between β1 and β2). In 
the TG ↔ HOMA-models analysis, the path coefficients 
did not differ significantly between β1 and β2. HDL-C had 
temporal patterns similar to those noted above for TG. 
Based on the unidirectional relationships from TG and 
HDL-C to Gutt index and 2-h insulin, the temporal rela-
tionship between Gutt index and 2-h insulin was further 
Fig. 1 The detailed parameter information on cross-lagged path analysis models. Results were adjusted for age, gender, smoking, alcohol 
consumption, regular exercise, BMI and caloric intake. a–d β1, cross-lagged path coefficients from baseline TG/HDL-C to follow-up Gutt index; β2, 
cross-lagged path coefficients from baseline Gutt index to follow-up TG/HDL-C; e: β1, cross-lagged path coefficients from baseline 2-h insulin to 
follow-up Gutt index; β2, cross-lagged path coefficients from baseline Gutt index to follow-up 2-h insulin; r1 represents synchronous correlations; r2 
and r3 represents tracking correlations; R
2: variance explained. aVariance explained when TG included; b variance explained when HDL-C included; 
**P < 0.01, *P < 0.05 for coefficients being different from 0; †Difference between β1 and β2 for being different from 0; TG, triglycerides; HDL-C, high-
density lipoprotein cholesterol; BMI, body mass index; Gutt index = [75,000 + (fasting glucose − 2-h glucose) × 0.19 × body weight]/(120 × log 
[(fasting insulin + 2-h insulin)/2] × [(fasting glucose + 2-h glucose)/2])
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examined. The path coefficient (β1) from the baseline 
2-h insulin to the follow-up Gutt index was significantly 
greater than the path coefficient (β2) from the baseline 
Gutt index to the follow-up 2-h insulin (P < 0.001 for the 
difference between β1 and β2).
The cross-lagged path analyses were also performed 
in separate models by gender, menopausal status and 
HOMA-IR status, with adjustments for age, gender 
(only for HOMA-IR analysis models), smoking, alcohol 
consumption, regular exercise, BMI, and caloric intake. 
The cross-lagged path coefficients did not differ signifi-
cantly between males and females or between pre- and 
post-menopausal females (Additional files 1: Table  S2 
and Table  S3). According to the HOMA-IR status, the 
unidirectional relationship from baseline TG or HDL-C 
to follow-up Gutt index did not change between the two 
groups. However, the path coefficients (β1) from baseline 
TG or HDL-C to the Gutt index in the IR group were sig-
nificantly greater than that in the normal group (Table 3).
The mediation analysis
Figure  2 showed the mediating effects of follow-up 2-h 
insulin on the unidirectional relationship from baseline 
TG/HDL-C to the follow-up Gutt index after adjusting 
for age, gender, smoking, alcohol consumption, regular 
exercise, BMI and caloric intake. The total effects of TG 
and HDL-C on the Gutt index were −0.166 for TG and 
0.108 for HDL-C (P < 0.001). The percentage of the total 
effects that were mediated by 2-h insulin were estimated 
to be 59.3% for TG (P  <  0.001) and 61.0% for HDL-C 
(P  <  0.001). Mediation analysis was also performed by 
HOMA-IR status. The direct effect of TG on Gutt index 
in the IR group was significantly greater than that in the 
normal group (direct effect  =  0.0701, 95% CI 0.02–
0.114, P = 0.02), which reduced the percentage of medi-
ating effect of 2-h insulin.
The sensitivity analysis
Three sensitivity analyses were conducted in this study. 
One obtained percentile bootstrap confidence intervals 
to evaluate sensitivity to the distributions of cross-lagged 
path coefficients. The second sensitivity analysis exam-
ined yearly rates of change (adjusted with age, gender, 
smoking, alcohol consumption, regular exercise, BMI 
and caloric intake) in TG, HDL-C, HOMA-models, Gutt 
index and 2-h insulin according to quartiles of their base-
line values using general linear models to validate the 
results of cross-lagged path analyses (Fig.  3; Additional 
Table 1 Linear regression analysis of baseline blood lipids with follow-up IR-related indices
β, regression coefficient; Std β, standard regression coefficient; TCHO, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; BMI, body mass index
Gutt index = [75,000 + (fasting glucose − 2-h glucose) × 0.19 × body weight]/(120 × log [(fasting insulin + 2-h insulin)/2] × [(fasting glucose + 2-h glucose)/2])
a Each regression model includes a single baseline blood lipid plus age, gender, smoking, alcohol consumption, regular exercise, caloric intake, BMI and dependent 
variable at baseline






Univariate modela Multiple modelb
β Std β P β Std β P
Ln (TCHO) Ln (Gutt index) −0.083 −0.038 0.017 −0.022 −0.010 0.536
Ln (HOMA-IR) 0.520 0.079 <0.001 0.221 0.031 0.086
Ln (HOMA-%β) −0.313 −0.050 0.005 −0.216 −0.030 0.080
Ln (2-h insulin) 0.079 0.020 0.233 −0.055 −0.014 0.423
Ln (TG) Ln (Gutt index) −0.098 −0.131 <0.001 −0.094 −0.125 <0.001
Ln (HOMA-IR) 0.342 0.154 <0.001 0.294 0.132 <0.001
Ln (HOMA-%β) 0.345 0.156 <0.001 −0.298 0.135 <0.001
Ln (2-h insulin) 0.174 0.129 <0.001 0.173 0.129 <0.001
Ln (HDL-C) Ln (Gutt index) 0.073 0.126 <0.001 0.072 0.124 <0.001
Ln (HOMA-IR) −0.215 0.122 <0.001 −0.201 −0.114 <0.001
Ln (HOMA-%β) 0.212 0.121 <0.001 0.198 0.113 <0.001
Ln (2-h insulin) −0.114 −0.109 <0.001 −0.108 −0.104 <0.001
Ln (LDL-C) Ln (Gutt index) −0.010 −0.010 0.658 – – –
Ln (HOMA-IR) 0.037 0.013 0.467 – – –
Ln (HOMA-%β) −0.084 −0.030 0.092 – – –
Ln (2-h insulin) −0.027 −0.015 0.366 – – –
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Table 2 The cross-lagged path coefficients with adjustment for covariates
Data are cross-lagged path coefficients and its 95% confidence interval with bootstrap simulation
Covariates included age, gender, BMI, alcohol consumption, smoking, regular exercise and caloric intake
TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; RMR, root mean square residual; CFI, comparative fitness index
Gutt index = [75,000 + (fasting glucose − 2-h glucose) × 0.19 × body weight]/(120 × log [(fasting insulin + 2-h insulin)/2] × [(fasting glucose + 2-h glucose)/2])
a Model 1: β1 describes the path from the baseline TG/HDL-C to the follow-up Gutt index, HOMA-models or 2-h insulin, and β2 describes the path from the baseline 
Gutt index, HOMA-models or 2-h insulin to the follow-up TG/HDL-C
b Model 2: β1 describes the path from the baseline 2-h insulin to the follow-up Gutt index, and β2 describes the path from the baseline Gutt index to the follow-up 2-h 
insulin
c P value for the difference between β1 and β2
* P < 0.05 for β1 and β2 being different from 0, ** P < 0.01 for β1 and β2 being different from 0
Path coefficients Goodness‑of‑fit 
model
β1 β2 P value
c RMR CFI
Model 1a
 TG ↔ Gutt index −0.131 (−0.168 to −0.099)** −0.047 (−0.072 to −0.010)* <0.001 0.048 0.916
 HDL-C ↔ Gutt index 0.134 (0.103 to 0.167)** 0.023 (−0.012 to 0.057) <0.001 0.021 0.970
 TG ↔ HOMA-IR 0.088 (0.055 to 0.121)** 0.086 (0.049 to 0.123)** 0.934 0.038 0.934
 HDL-C ↔ HOMA-IR −0.092 (−0.119 to −0.061)** −0.122 (−0.150 to −0.099)** 0.216 0.040 0.914
 TG ↔ HOMA-%β −0.089 (−0.119 to −0.057)** −0.084 (−0.109 to −0.060)** 0.837 0.058 0.895
 HDL ↔ HOMA-%β 0.089 (0.061 to 0.120)** 0.119 (0.096 to 0.151)** 0.216 0.039 0.941
 TG ↔ 2-h Insulin 0.125 (0.090 to 0.159)** 0.040 (0.010 to 0.068)* <0.001 0.045 0.919
 HDL-C ↔ 2-h Insulin −0.112 (−0.146 to −0.080)** −0.026 (−0.056 to 0.010) <0.001 0.041 0.987
Model 2b
 2-h insulin ↔ Gutt index −0.121 (−0.162 to −0.081)** −0.036 (−0.079 to 0.010) <0.001 0.059 0.884
Table 3 The cross-lagged path coefficients by HOMA-IR status in the total sample, with adjustment for covariates
Data are cross-lagged path coefficients
NS, non-significant; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index
Gutt index = [75,000 + (fasting glucose − 2-h glucose) × 0.19 × body weight]/(120 × log [(fasting insulin + 2-h insulin)/2] × [(fasting glucose + 2-h glucose)/2])
Covariates included age, gender, BMI, alcohol consumption, smoking, regular exercise and caloric intake
a Model 1: β1 describes the path from the baseline TG/HDL-C to the follow-up Gutt index, HOMA-models or 2-h insulin, and β2 describes the path from the baseline 
Gutt index, or 2-h insulin to the follow-up TG/HDL-C
b Model 2: β1 describes the path from the baseline 2-h insulin to the follow-up Gutt index, and β2 describes the path from the baseline Gutt index to the follow-up 2-h 
insulin
c Insulin resistance (IR) was defined as the upper quartile of HOMA-IR
* P < 0.05 for β1 and β2 being different from 0, ** P < 0.01 for β1 and β2 being different from 0
Normal (n = 2, 516) IR (n = 809)c IR status difference
β1 β2 β1 β2 P for β1 P for β2
Model 1a
TG ↔ Gutt index −0.094** −0.029 −0.173** 0.040 0.047 NS
HDL-C ↔ Gutt index 0.091** 0.016 0.177** 0.016 0.030 NS
TG ↔ HOMA-%β −0.103* −0.117* −0.051 −0.047 NS NS
HDL ↔ HOMA-%β 0.093** 0.136** 0.114** 0.062 NS NS
TG ↔ 2-h insulin 0.113** 0.044* 0.128* 0.029 NS NS
HDL-C ↔ 2-h insulin −0.094** −0.020 −0.147** −0.010 NS NS
Model 2b NS NS
2-h insulin ↔ Gutt index −0.095** −0.023 −0.153** −0.025 NS NS
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file 2: Fig. S1, Additional file 3: Fig. S2, Additional file 4: 
Fig.  S3). For example, the yearly rate of change in the 
Gutt index during the follow-up period significantly var-
ied across increasing quartiles of baseline TG (P < 0.001) 
(Fig.  3a), however, the yearly rate of change in TG did 
not show a significantly varying trend across quar-
tiles of baseline Gutt index (P =  0.095) (Fig.  3c). These 
results were consistent with the temporal relationships 
in the cross-lagged models shown in Table 2 and Fig. 1. 
The third sensitivity analysis used other insulin sensitiv-
ity indices such as Stumvoll index and Avignon index 
instead of Gutt index in the cross-lagged path analysis. 
The results of the Stumvoll index and Avignon index 
were similar to that of the Gutt index (Additional file 1: 
Table  S4). Selection of different indices for IR probably 
did not affect the consequence of these analyses.
Discussion
In this study, we found for the first time that changes in 
TG and HDL-C have unidirectional relationships with 
peripheral IR and bidirectional relationships with hepatic 
IR by cross-lagged path analysis. 2-h insulin partially 
mediated the effects of TG and HDL-C on peripheral 
IR, with a 59.3% mediating effect for TG and a 61.0% 
Fig. 2 Mediating effects of follow-up 2-h insulin on the association between baseline TG/HDL-C and follow-up Gutt-index. Mediation analysis 
was used with adjustment for age, gender, BMI, alcohol consumption, smoking, regular exercise and caloric intake. Data are standard regression 
coefficients and 95% CI. Effect different from 0: **P < 0.01. BMI, body mass index; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; 
CI, confidence interval; Gutt index = [75,000 + (fasting glucose − 2-h glucose) × 0.19 × body weight]/(120 × log [(fasting insulin + 2-h insu-
lin)/2] × [(fasting glucose + 2-h glucose)/2])
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mediating effect for HDL-C. Gender and menopausal 
status had no effect on these temporal relationships.
In this study, we examined the temporal relationships 
between blood lipids and IR using cross-lagged path anal-
ysis, which is a powerful statistical approach in dissecting 
a causal relationship between inter-correlated variables. 
Two unidirectional relationships from TG and HDL-C to 
peripheral IR were confirmed in our analyses, suggesting 
a potential causal role for TG and HDL-C in the etiol-
ogy of peripheral IR. Our results are supported by some 
human studies. For example, IR is not independently 
associated with future dyslipidemia when visceral adi-
pose tissue included [20], genetic studies have shown that 
mutations in some genes that only involved in lipoprotein 
pathways cause dyslipidemia, which consequently lead to 
IR [21–24], and intervention studies have suggested that 
controlling dyslipidemia can improve IR [25–27]. Basic 
and animal studies may provide potential mechanisms of 
these unidirectional relationships. The metabolites of TG 
such as free fatty acids (FFAs), diacylglycerol and etc. can 
regulate insulin-signaling pathways through activating 
several serine/threonine kinases, which suppress insulin 
receptor and tyrosine phosphorylation of insulin receptor 
substrates, inducing peripheral IR [1, 28, 29]. HDL-C can 
improve peripheral IR probably through multiple mech-
anisms, including: (1) suppression of inducible nitric 
oxide synthase and fatty acid synthase; (2) regulation of 
fat storage in adipocytes via upregulation of the uncou-
pling protein, and inducing the phosphorylation of AMP 
kinase in myocytes and liver by its principal apolipopro-
tein moiety, apoA-1 [30, 31]. In terms of hepatic IR, we 
found bidirectional relationships of TG and HDL-C with 
hepatic IR, which were different from that with periph-
eral IR. Although hepatic IR is frequently associated with 
peripheral IR, the severity of IR may differ among the 
various tissues in different individuals [32]. This indicates 
that treatment for IR should be organ-specific.
Further, we found changes in TG and HDL-C preceded 
changes in 2-h insulin concentration. The effect of TG/
FFA cycle on lipid signaling of β-cells is likely one pri-
mary mechanism of these unidirectional relationships 
[33]. The intermediates within the TG/FFA cycle can 
increase insulin secretion in β-cells through: (1) activat-
ing lipases from islet tissue; (2) activating protein kinase 
Fig. 3 The yearly-rates of change () in TG, HDL-C and Gutt index by quartiles of their baseline-values. General linear model was used to compare 
yearly change rates in TG, HDL-C and Gutt index across quartiles of their baseline values, with adjustment for age, gender, smoking, alcohol con-
sumption, regular exercise, BMI and caloric intake. BMI, body mass index; TG, fasting triglycerides; HDL-C, high-density lipoprotein cholesterol; Gutt 
index = [75,000 + (fasting glucose − 2-h glucose) × 0.19 × body weight]/(120 × log [(fasting insulin + 2-h insulin)/2] × [(fasting glucose + 2-h 
glucose)/2])
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C; (3) alteration of membrane physicochemical proper-
ties of β-cells [34–38]. Moreover, FFA forms from hydrol-
ysis of TG can cross β-cell membrane and active β-cell 
surface fatty acids receptor, which causes an increase in 
intracellular Ca2+, leading to increased insulin secretion 
[39, 40]. In addition, HDL-C regulates insulin secretion 
through regulation of cholesterol homeostasis in β-cells 
via ATP-binding cassette transporters [41, 42]. Increased 
in HDL-C can reduce β-cell cholesterol content in mice 
with dyslipidemia, which consequently influence β-cell 
function [43].
We also found change in 2-h insulin preceded periph-
eral IR. Catherine Le Stunff et  al. showed that early 
change in postprandial insulin concentration, not in insu-
lin sensitivity, was associated with obesity in early life. 
This study suggested that postprandial insulin may play 
an earlier role than peripheral IR in the development of 
metabolic defects throughout the whole body [44], fur-
ther supporting our result in this study. Some mecha-
nisms may also support the result that increased insulin 
concentration preceded peripheral IR. Increased insulin 
concentration can cause peripheral IR by mediating its 
own signaling pathway through: (1) diminishing insulin 
receptors affinity and insulin receptor’s kinase activity, 
(2) reducing the number of insulin receptors exposed on 
the cell surface by promoting internalization and degra-
dation of hormone-occupied receptors [45].
Because the unidirectional relationships from TG and 
HDL-C to 2-h insulin, and from 2-h insulin to peripheral 
IR were established in this study, these findings prompted 
us to hypothesize that 2-h insulin concentration prob-
ably played mediating roles in the temporal relation-
ships of TG and HDL-C with peripheral IR. The results 
of mediation analysis in this study did, in fact, show that 
2-h insulin partially mediated the temporal relationships 
with a 59.3% mediating effect for TG and a 61.0% medi-
ating effect for HDL-C. Moreover, hepatic IR probably 
influences this mediating effect. Hepatic IR causes the 
overproduction of VLDL, which results in hypertriglyc-
eridemia. Hypertriglyceridemia probably augments the 
effect of TG on the peripheral IR and reduces the per-
centage of mediating effect of 2-h insulin.
This study emphasized the important roles of TG and 
HDL-C as plausible therapeutic targets for improving 
peripheral IR. It has been suggested that an imbalance 
in insulin action probably plays a vital role in the devel-
opment of metabolic abnormalities [46]. The results of 
this study indicated that changes in TG and HDL-C were 
likely causal factors of peripheral IR through influenc-
ing insulin action. Although TG could represent com-
bined mass of fasting or non-fasting triglyceride-rich 
lipoproteins [47], increase the risk of CVD and predict 
ten-year all-cause mortality in patients with T2D [48], 
the significance of TG as a plausible therapeutic target 
was underestimated for many years [49]. In China, dys-
lipidemia has increased significantly during the past dec-
ade. The prevalence rates of abnormal lipid levels were 
estimated at 30.7 and 13.8% for TG and HDL-C [50]. 
However, the awareness, treatment and control rates of 
dyslipidemia were estimated at 24.4, 8.8 and 4.3% [51]. It 
is urgent to initiate dyslipidemia intervention program 
for improving IR so as to reduce the burden of CVD and 
T2D.
Although postprandial hyperlipidemia probably played 
an important role of metabolic defects [52], this study did 
not include it based on the following reasons. First, the 
primary objective of this study is to examine the causal 
relationship between dyslipidemia and IR from epidemi-
ologically point for providing potential effectively treat-
ment target. Fasting lipidemia are more feasible than 
postprandial lipidemia as treatment targets in the pri-
mary care because time and labor intensive are probably 
two major constraints of postprandial lipidemia measure 
in large population-based survey. Second, insulin and TG 
peak frequently occurs at different time points after an 
oral fat test. It has been reported that TG concentration 
at 2  h after consumption is not associated with insulin 
secretion [53]. Third, fasting TG significantly correlates 
with fasting apolipoprotein B-48 concentration, which 
may represent the postprandial lipidemia response [54, 
55].
Strengths/weaknesses
This study examined the temporal relationships of blood 
lipids with IR using a novel theoretical model. Moreo-
ver, based on fasting and 2-h status, both hepatic and 
peripheral IR were included, providing more informa-
tion for these temporal relationships. Further, this study 
examined the potential mechanisms of these causal rela-
tionships using mediation analysis. However, this study 
also has some weaknesses. First, this study only included 
Asian subjects, which is likely to limit the generalizabil-
ity of our findings to other ethnic populations. Second, 
hepatic IR and peripheral IR were calculated based on 
glucose and insulin levels. The results of this study should 
be confirmed in other studies by more sophisticated 
methods such as glucose clamp technique and intrave-
nous glucose tolerance test.
In conclusion, by performing a longitudinal assessment 
of the temporal relationships of blood lipids with IR using 
cross-lagged path analysis models, this study is the first 
to find that changes in TG and HDL-C probably precede 
changes in peripheral IR. A significant causal mediating 
effect of 2-h insulin on the unidirectional relationships 
from blood lipids to IR were also demonstrated for the 
first time. These findings enhance our understanding of 
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the mechanisms of IR. Moreover, these results provide 
more evidence for the early prevention of IR by improv-
ing dyslipidemia.
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